The Fund's investment objective is to achieve long-term capital growth.
Name | % Net Assets |
---|---|
Booker Group | 4.2% |
Patsystems | 3.9% |
Immunodiagnostic Systems Hldgs | 3.6% |
Filtrona | 3.5% |
Omega insurance Holdings Ltd. | 3.3% |
John Menzies | 3.0% |
Pace | 2.9% |
Dignity | 2.8% |
Elements | 2.8% |
Xaar | 2.5% |
Key | % Net Assets |
---|---|
Booker Group | 4.2% |
Patsystems | 3.9% |
Immunodiagnostic Systems Hldgs | 3.6% |
Filtrona | 3.5% |
Other | 84.8% |
Date | 31-May-2023 |
---|---|
NAV | 427.20p |
Currency | GBP |
Change | -2.70p |
% | -0.63% |
YTD change | 427.20p |
YTD % | n/a |
Fund Inception | 02/08/1996 |
---|---|
Fund Manager | Paul Marriage |
TER | 1.26 (30-Apr-2011) |
Minimum Investment | |
---|---|
Initial | £25000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 1.00% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.26 |
You are here: research